Michael Wildes, MD
Cornea and External Diseases Specialist · Aurora, CONPI 1396163929
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Novartis at 25.3% of the total. Reporting peaked in 2022 at $361 and has fallen 90.0% since, to $36 in 2024.
Across 26 payments — averaging $41.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$272
- Oyster Point Pharma, Inc.$255
- Alcon$163
- Bausch & Lomb, A Division Of Bausch Health US, LLC$149
- Aerie Pharmaceuticals, Inc.$61
- Eyevance Pharmaceuticals LLC$42
- plus $133 from 5 others
What the payments were for
- Food & beverage$1,074100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 6 | $272 |
| Oyster Point Pharma, Inc. | 1 | $255 |
| Alcon | 3 | $163 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $149 |
| Aerie Pharmaceuticals, Inc. | 3 | $61 |
| Eyevance Pharmaceuticals LLC | 3 | $42 |
| Kala Pharmaceuticals, Inc. | 2 | $38 |
| Carl Zeiss Meditec, Inc. | 1 | $36 |
| AbbVie | 2 | $28 |
| Sight Sciences, Inc. | 1 | $19 |
| Ocular Therapeutix, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYRVAYA$255
- XIIDRA$121
- Clareon$115
- LOTEMAX SM$100
How this compares
Too few cornea and external diseases specialist providers in Coloradoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 63 | $71,138 |
| XiidraLifitegrast | 22 | $25,054 |
| Prednisolone Acetate | 429 | $15,750 |
| Restasis MultidoseCyclosporine | 15 | $9,812 |
| Ketorolac Tromethamine | 247 | $9,771 |
| Fluorometholone | 124 | $9,540 |
| Cyclosporine | 14 | $7,216 |
| MoxifloxacinMoxifloxacin Hcl | 124 | $3,685 |
| ValacyclovirValacyclovir Hcl | 46 | $3,633 |
| ErythromycinErythromycin Base | 107 | $1,356 |
| Loteprednol Etabonate | 12 | $1,064 |
| Difluprednate | 11 | $769 |
| Ofloxacin | 42 | $500 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 29 | $445 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 25 | $310 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Restasis Multidose | $28 | $80,95078 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $149 | $1,06412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Coloradoon file to place this against a meaningful peer group, so we don't.
Other cornea and external diseases specialist in Aurora
- Michael TaravellaAurora$12K
- Karen ChristopherAurora$3K
- Christopher GelstonAurora$2K
- Brittany PerziaAurora$956
- Aimee VernerLongmont$3K
- Christopher HamptonWheat Ridge$1K
- Ronald WiseDenver$1K
- James SbarbaroColorado Springs$1K
- Clayton FalknorColorado Springs$1K
- Marcus NeufferUsaf Academy$445
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.